 Home > Active Ingredient News > Antitumor Therapy > Leuk Lymphoma: CD19 CAR T therapy can be used to treat patients with recurrent Ph+ALL with T315I mutation

Leuk Lymphoma: CD19 CAR T therapy can be used to treat patients with recurrent Ph+ALL with T315I mutation

 Last Update: 2021-05-20
 Source: Internet
 Author: User

Tags

electricity 1 7

discovery target 2019

Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

At present, there are not many effective treatments for recurrent Ph+ALL with T315I mutation; CD19 CAR T is a potential therapy for such patients.

These 7 patients with recurrent Ph+ALL with T315I mutation received CD19-specific CAR T cell therapy before or after allo-HSCT.

The results showed that of these 7 cases, 6 entered CR or CRp within 1 month after the first CAR T cell infusion.

In summary, the results of this study confirmed the efficacy of anti-CD19 CAR T cell therapy in the treatment of recurrent Ph+ALL with T315I mutation before and after allo-HSCT, and the therapy can be used in combination with Pranatinib.

Original source:

Fei Yang, et al.

ncbi.
nlm.
nih.
gov/31512942/" target="_blank" rel="noopener">Anti-CD19 chimeric antigen receptor T- cells induce durable remission in relapsed Philadelphia chromosome-positive ALL with T315I mutation

in this message

This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

Related Products

Gefitinib

CAS No.: 184475-35-2

Pharmacy Grade

$1/MT FOB

High quality Sunitinib CAS NO 557795-19-4 Orange solid powder 99% API for antitumor

CAS No.: 557795-19-4

Pharmacy Grade

$4.1-4.2/G FOB

Epirubicin

CAS No.: 56420-45-2

$1/KG EXW

Hot Tags

united states jobs(223)

jobs united states(236)

1 year treasury(277)

1 year subscription(296)

announcements today(81)

80 20 company(94)

united states logo(227)

single use technology(195)

healthy food name(42)

ups united states(221)

Hot Articles

The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.